Non-Cardiac Surgery with Incomplete Revascularization, Associated to Events

This study presented at the American Heart Association Scientific Sessions 2016 and simultaneously published in the Journal of the American College of Cardiology, showed incomplete revascularization is associated with an increased risk of adverse cardiac events, particularly infarction, in patients that must later receive non-cardiac surgery.

 

Patients with incomplete revascularization (defined as a ≥ 50% left main lesion or a ≥ 70% lesion in any major epicardial vessel) have a 19% higher risk of events at 30 days when facing non-cardiac surgery vs. patients with complete revascularization (p=0.05).

 

The difference was basically driven by a 37% increase in infarction risk (p=0.01). For each unrevascularized vessel, perioperative infarction risk increased 17% (p<0.001).

 

The study included 12,486 patients undergoing PCI and subsequent non-cardiac surgery. Of these patients, 35% arrived to the OR with incomplete revascularization.

 

Prior evidence is from the CARP study (Coronary Artery Revascularization Prophylaxis), which included 5,859 patients with prior revascularization surgery programed to receive non-cardiac surgery.

 

In the CARP study, revascularization did not change long term events rate, which led to minimizing revascularization prior to surgery. However, the CARP study was published ten years ago.

 

In this new study, researchers have found out a significant interaction with the time of non-cardiac surgery. Patients undergoing non cardiac surgery 6 weeks before PCI with incomplete revascularization had 84% more perioperatory risk compared to those with complete revascularization operated within the same timeframe.

 

Risk was no higher in those operated beyond 6 weeks after PCI.

 

One of the limitations to this study is that it was not possible to determine the type of post operatory MI. They could have been caused by either troponin elevation, plaque rupture or stent thrombosis.

 

Original Title: Incomplete revascularization is associated with an increased risk of major adverse cardiovascular events among patients undergoing non-cardiac surgery.

Presenter:  Armstrong EJ.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...